Citations

Showing 10 of 108104 citations.

Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Misra, Anisha , Theel, Elitza S.

Mayo Clinic

Journal of Clinical Microbiology | March 7, 2022 | Volume: 60 | Issue: 6 | Pages: No page available

10.1128/jcm.00482-21 | PMID 35249377 Get It

Preexisting immunity to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was nonexistent in humans, which coupled with high transmission rates of certain SARS-CoV-2 variants and limited vaccine uptake or availability, has collectively resulted in an ongoing global pandemic. The identification and establishment of one or multiple correlates of protection (CoP) against infectious pathogens is challenging, but beneficial from both the patient care and public health perspectives.
Emerging immunotherapy for HCC: A guide for hepatologists
Foerster, Friedrich , Gairing, Simon Johannes , Ilyas, Sumera I. , Galle, Peter R. , Ilyas, Sumera Irie , Galle, Peter Robert

Mayo Clinic

Hepatology | March 7, 2022 | Volume: 75 | Issue: 6 | Pages: 1604-1626

10.1002/hep.32447 | PMID 35253934 Get It

Abstract HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐related death globally. HCC comprises nearly 90% of all cases of primary liver cancer. Approximately half of all patients with HCC receive systemic therapy during their disease course, particularly in the advanced stages of disease. Immuno‐oncology has been paradigm shifting for the treatment of human cancers, with strong and durable antitumor activity in a subset of patients across a variety of malignancies including HCC. Immune checkpoint inhibition with atezolizumab and bevacizumab, an antivascular endothelial growth factor neutralizing antibody, has become first‐line therapy for patients with advanced HCC. Beyond immune checkpoint inhibition, immunotherapeutic strategies such as oncolytic viroimmunotherapy and adoptive T‐cell transfer are currently under investigation. The tumor immune microenvironment of HCC has significant immunosuppressive elements that may affect response to immunotherapy. Major unmet challenges include defining the role of immunotherapy in earlier stages of HCC, evaluating combinatorial strategies that use targeting of the immune microenvironment plus immune checkpoint inhibition, and identifying treatment strategies for patients who do not respond to the currently available immunotherapies. Herein, we review the rationale, mechanistic basis and supporting preclinical evidence, and available clinical evidence for immunotherapies in HCC as well as ongoing clinical trials of immunotherapy.
Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS
Zeydan, Burcu , Rocca, Maria A. , Kantarci, Orhun H. , Filippi, Massimo , Filippi, Massimo , Zeydan, Burcu , Rocca, Maria A

Mayo Clinic

Annals of Neurology | March 7, 2022 | Volume: 91 | Issue: 5 | Pages: 734-735

10.1002/ana.26341 | PMID 35253269 Get It

Development and Validation of Instrument for Operative Competency Assessment in Selective Neck Dissection
Dowling, Eric M. , Larson, David, Carlson, Matthew L. , Dowling, Eric , Price, Daniel L.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | March 7, 2022 | Volume: 132 | Issue: 2 | Pages: 173-181

10.1177/00034894221081101 | PMID 35249359 Get It

Background: Instruments to assess surgical skills have been validated for several key indicator procedures in otolaryngology. Selective neck dissection is a core procedure for which trainees must integrate knowledge of complex head and neck anatomy with technical surgical skills. An instrument for assessment of surgical performance in selective neck dissection has not been previously developed. The objective of the current study is to develop and validate an instrument for assessing surgical competency for level II-IV selective neck dissection. Design: A Delphi working group comprised of 23 fellowship trained head and neck surgeons from 17 institutions was assembled. The modified Delphi method encompassed a 3-step process, including 2 anonymous voting rounds to successively refine individual items and establish levels of consensus. Thresholds for achieving strong consensus, at >80% agreement, were determined a priori. The resulting instrument was subsequently validated in a prospective cohort of 17 resident surgeons, spanning postgraduate year 1 to 5 training experience. Participants were asked to perform a level II-IV selective neck dissection on fresh-frozen cadaveric specimens. Performance was scored by 2 independent, blinded observers using the devised instrument and construct validity was assessed. Results: Through the modified Delphi process a final list of 30 items, considered to be the most essential items for achieving the goals of a level II-IV selective neck dissection, was developed. Construct validity was supported by a positive association between instrument scores compared to both resident postgraduate year level and number of head and neck rotations completed. Conclusion: The development and validation of a novel instrument for assessment of surgical competency in level II-IV selective neck dissection, a key indicator case in otolaryngology, is described. This new instrument may be used to provide objective feedback on overall and task-specific competency to identify surgical deficiencies and offer granular feedback to enhance surgical training.
Surgical treatment of spinal cord compression due to Hirayama disease: illustrative case
Hudson, Miles , Meyer, Jenna H., Neal, Matthew T. , Patel, Naresh P. , Singh, Rohin

Mayo Clinic

Journal of Neurosurgery: Case Lessons | March 7, 2022 | Volume: 3 | Issue: 10 | Pages: No page available

10.3171/case21697 | PMID 36130535 Get It

BACKGROUND Hirayama disease (HD), also known as juvenile spinal muscular atrophy, is a rare condition in which flexion of the cervical neck causes compression and ischemic changes to the anterior horns of the spinal cord. Here the authors presented the first reported case of HD in North America that was successfully treated via surgical intervention. OBSERVATIONS The patient was a 15-year boy with insidious onset upper limb weakness and atrophy. His findings were a classic presentation of HD although his complex history and relative rarity of the disease caused him to remain undiagnosed for months. After conservative management via cervical collar failed, the patient was successfully treated via C5-C7 anterior cervical discectomy and fusion. The patient’s symptoms stabilized by the 3-month follow-up. LESSONS The diagnosis of HD is easy to miss because of the lack of reporting and widespread knowledge of this condition in North America. Thus, when presented with a case of insidious onset limb weakness in a juvenile patient, HD should be placed on the differential list and verified with cervical flexion magnetic resonance imaging. Additionally, surgical intervention should be considered a safe and effective option for HD when conservative methods have failed.
Surgical Trigger Finger Release Is Associated With New-Onset Dupuytren Contracture in the Short-Term Postoperative Period: A Matched Analysis
Maasarani, Samantha , Wee, Corinne, Lee, Christina D., Khalid, Syed , Layon, Sarah A. , Noland, Shelley S.

Mayo Clinic

HAND | March 7, 2022 | Volume: 18 | Issue: 7 | Pages: 1080-1088

10.1177/15589447221077375 | PMID 35253506 Get It

Background: This article compares the rates and time-to-development of new-onset Dupuytren disease in patients with trigger finger treated by steroid injection, surgical release, or both. Methods: PearlDiver’s Mariner 30 database was queried to identify patients with trigger finger between January 2010 and June 2019. One-to-one exact matching based on baseline patient demographics allowed us to create 4 identical groups defined by the type of trigger finger intervention received. Results: The matched population analyzed in this study consisted of 85 944 patients who were equally represented in the steroid injection cohort (n = 21 486, 25.00%), surgical release cohort (n = 21 486, 25.00%), steroids prior to surgery cohort (n = 21 486, 25.00%), and no intervention (control) cohort (n = 21 486, 25.00%). A new Dupuytren diagnosis after trigger finger treatment occurred in 1 in 128 patients overall, 1 in 156 patients treated with steroid injection, and 1 in 126 patients treated with surgical release. Trigger fingers treated by steroid injection only had the lowest rates of Dupuytren disease overall (n = 137, 0.64%, P = .0424) and treatment with fasciectomy (n = 14, 0.07%, P < .0005). In all, 171 patients in the surgery cohort developed Dupuytren disease 1 year after undergoing surgical trigger finger release. Furthermore, this cohort had the highest rates of fasciectomy (n = 55, 0.26%, P < .0005) and the lowest rates of no intervention (n = 103, 0.48%, P = .0471). Trigger fingers managed by surgical release developed Dupuytren disease (mean, 56.11 days; SD, 80.93 days, log-rank P = .02) and underwent fasciectomy (mean, 49.74 days; SD, 62.27 days; log-rank P < .0005) more quickly than all other cohorts. Conclusions: Patients solely undergoing surgical release of their trigger finger had significantly higher odds and expedited rate of developing new-onset Dupuytren disease overall and undergoing subsequent treatment by fasciectomy compared with trigger fingers managed by other interventions.
Development and Feasibility of a Multidisciplinary Approach to AKI Survivorship in Care Transitions: Research Letter
Frazee, Erin N. , Schreier, Diana J., Meade, Laurie A., Anderson, Brenda, Rensing, Megan E., Ruud, Kari L., Kattah, Andrea G. , Finnie, Dawn M., Herges, Joseph R. , Group, For the ACT Study, Frazee, Erin N , Anderson, Brenda K, Kattah, Andrea G , May, Heather P. , Rule, Andrew D. , McCoy, Rozalina G. , Kashani, Kianoush , Group, For the ACT Study

Mayo Clinic

Canadian Journal of Kidney Health and Disease | March 7, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/20543581221081258 | PMID 35284082 Get It

Background: Acute kidney injury (AKI) survivors are at heightened risk for poor short- and long-term health outcomes. Even among those who recover after an AKI episode, the risk for chronic kidney disease is 4- to 6-fold higher than in patients without AKI, underscoring the importance of identifying methods to improve AKI survivorship. Objective: The purpose of this report was to describe the development and feasibility of a novel multidisciplinary approach to caring for AKI survivors at care transitions (ACT). Design: Observational process improvement initiative. Setting: Single academic medical center in the United States. Patients: The studied population was adults with stage 3 AKI not discharging on dialysis who were established with a primary care provider (PCP) at our institution. Methods: An electronic health record tool was developed prior to implementation to identify AKI survivors. The ACT program encompassed engaging patients in the hospital, delivering education by nephrology-trained nurses before discharge, completing recommended laboratory testing after discharge, and conducting structured kidney-focused follow-up with a pharmacist and a PCP within 7 to 14 days after discharge. Patients could be referred for nephrology evaluation at the discretion of the PCP. Results: Preliminary data demonstrated that most AKI survivors of interest could be identified, educated, and followed up with this model. This strategy appeared feasible, scalable, and maximized the unique expertise of each member of the multidisciplinary team. Limitations: Small sample size, future assessment of process, clinical, and patient-reported outcomes needed. Conclusions: The multidisciplinary ACT workflow supported by clinical decision support was feasible and addressed gaps in existing care transition models. Team-based care delivery in primary care appears to be a mechanism to extend the capacity for kidney health monitoring for AKI survivors.
Association of Perinatal Factors With Severe Obesity and Dyslipidemia in Adulthood
Tadese, Kristene , Ernst, Vivian, Weaver, Amy L. , Thacher, Tom D. , Rajjo, Tamim , Kumar, Seema , Kaufman, Tara K. , Lynch, Brian , Kaufman, Tara , Lynch, Brian A , Thacher, Thomas D , Ernst, Vivian, Wi, Chung‐Il

Mayo Clinic

Journal of Primary Care & Community Health | March 6, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501327211058982 | PMID 35249418 Get It

Background: Perinatal factors including gestational age, birthweight, size for gestational age, delivery route, maternal parity, maternal age, maternal education, socioeconomic status, race, and sex, are associated with the future risk of obesity and co-morbid conditions. This study evaluated the relationship of birthweight for gestational age and perinatal factors with severe obesity and dyslipidemia in adulthood. Methods: We conducted a population-based, retrospective birth cohort study of infants born to residents of Olmsted County, MN between 1976 and 1982. Outcomes were assessed after age 18 years until October 2020, including severe obesity (BMI ≥ 40 kg/m 2 ) and dyslipidemia (total cholesterol ≥200 mg/dL, non-high density lipoprotein [non-HDL] cholesterol ≥145 mg/dL or HDL cholesterol <40 mg/dL). We obtained mother’s age, education level, and parity as well as newborn sex, race, type of delivery, single/multiple birth, gestational age, and birthweight from birth certificate data. Individual-level socioeconomic status (SES) of the household at birth was determined with the HOUSES index. Results: Of 10 938 birth cohort subjects, 7394 had clinic visits after age 18 years and were included, with 2630 having severe obesity (n = 798) or dyslipidemia (n = 2357) as adults. In multivariable models, female sex, singleton birth, less maternal education, and lower SES defined by HOUSES were independently associated with an increased risk of severe obesity in adulthood. Non-white race, singleton birth, and lower birthweight were independently associated with adult dyslipidemia. Birthweight for gestational age was not associated with severe obesity or dyslipidemia. Conclusion: Perinatal factors were associated with both severe obesity and dyslipidemia in adulthood. Lower SES at birth was predictive of severe obesity in adulthood, highlighting the opportunity to investigate modifiable perinatal social determinants to reduce the risk of severe obesity.
Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group
Crane, Jacquelyn , Xue, Wei , Qumseya, Amira, Gao, Zhengya, Arndt, Carola A.S., Donaldson, Sarah S. , Harrison, Douglas J. , Hawkins, Douglas S. , Linardic, Corinne M. , Mascarenhas, Leo , Meyer, William H. , Rodeberg, David A. , Rudzinski, Erin R. , Walterhouse, David , Venkatramani, Rajkumar , Crane, Jacquelyn N , Shulkin, Barry L , Hawkins, Douglas S , Donaldson, Sarah S , Mascarenhas, Leo , Shulkin, Barry L. , Weiss, Aaron R.

Mayo Clinic

Pediatric Blood & Cancer | March 6, 2022 | Volume: 69 | Issue: 6 | Pages: No page available

10.1002/pbc.29644 | PMID 35253352 Get It

Abstract The Children's Oncology Group (COG) uses Clinical Group (CG) and modified Tumor Node Metastasis (TNM) stage to classify rhabdomyosarcoma (RMS). CG is based on surgicopathologic findings and is determined after the completion of initial surgical procedure(s) but prior to chemotherapy and/or radiation therapy. The modified TNM stage is based on clinical and radiographic findings and is assigned prior to any treatment. These systems have evolved over several decades. We review the history, evolution, and rationale behind the current CG and modified TNM classification systems used by COG for RMS. Data from the seven most recently completed and reported frontline COG trials (D9602, D9802, D9803, ARST0331, ARST0431, ARST0531, ARST08P1) were analyzed, and confirm that CG and modified TNM stage remain relevant and useful for predicting prognosis in RMS. We propose updates based on recent data and discuss factors warranting future study to further optimize these classification systems.
Clinical Outcomes of Ahmed ClearPath Implantation in Glaucomatous Eyes: A Novel Valveless Glaucoma Drainage Device
Grover, Davinder S. , Kahook, Malik Y., Seibold, Leonard K., Singh, Inder Paul, Ansari, Husam, Butler, Michelle R., Smith, Oluwatosin , Sawhney, Gagan, Tassel, Sarah H. Van, Dorairaj, Syril

Mayo Clinic

Journal of Glaucoma | March 6, 2022 | Volume: 31 | Issue: 5 | Pages: 335-339

10.1097/ijg.0000000000002013 | PMID 35249988 Get It

Précis: Designed with novel features to facilitate implantation and improve safety, the Ahmed ClearPath (ACP) glaucoma drainage device (GDD) provided intraocular pressure (IOP) reduction comparable with other GDDs in eyes with refractory glaucoma in a multicenter retrospective study. Purpose: To present clinical outcomes with a novel valveless GDD (ACP, New World Medical). The 250 and 350 mm2 models feature a contoured plate for optimal globe apposition, anteriorized suture points to facilitate suturing to the globe, and a prethreaded 4-0 polypropylene ripcord suture. Methods: This was a multicenter retrospective analysis of eyes with medically and/or surgically uncontrolled glaucoma implanted with the 250 or 350 mm2 ACP either as a standalone procedure or in combination with other procedures. Pre-, intra-, and postoperative data through 6 months were collected. Results: A total of 104 eyes (100 subjects) received the ACP by 10 US surgeons, 63.5% of which had primary open-angle glaucoma and 62.5% had severe glaucoma. Mean baseline IOP was 26.3 (9.0) mm Hg and mean medication use was 3.9 (1.3). Through 6 months’ follow-up, mean IOP ranged from 13.6 to 16.7 mm Hg and mean medication use from 0.9 to 1.9 medications (P<0.0001 at all timepoints for each outcome measure). At 6 months, mean IOP was 13.7 mm Hg (−13.0 mm Hg, 43.0%, P<0.0001) and mean medication use was 1.9 medications per eye (−2.1, 47.7%, P<0.0001). Common adverse events included anterior chamber inflammation (16.3%), hyphema (15.4%), and hypotony (6.7%). Conclusion: The new ACP appears to be safe and efficacious as a standalone procedure or in combination with other procedures for uncontrolled glaucoma, and may be considered as a GDD option for patients in whom its unique design may facilitate the implantation process.